MX2014003467A - Romidepsina y 5-azacitidina para el tratamiento de linfoma. - Google Patents

Romidepsina y 5-azacitidina para el tratamiento de linfoma.

Info

Publication number
MX2014003467A
MX2014003467A MX2014003467A MX2014003467A MX2014003467A MX 2014003467 A MX2014003467 A MX 2014003467A MX 2014003467 A MX2014003467 A MX 2014003467A MX 2014003467 A MX2014003467 A MX 2014003467A MX 2014003467 A MX2014003467 A MX 2014003467A
Authority
MX
Mexico
Prior art keywords
day
romidepsin
azacytidine
administered
approximately
Prior art date
Application number
MX2014003467A
Other languages
English (en)
Spanish (es)
Inventor
Reinhard Dummer
Sima Rozati
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2014003467A publication Critical patent/MX2014003467A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014003467A 2011-09-23 2012-09-21 Romidepsina y 5-azacitidina para el tratamiento de linfoma. MX2014003467A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161538734P 2011-09-23 2011-09-23
US201261698441P 2012-09-07 2012-09-07
PCT/US2012/056485 WO2013043967A1 (en) 2011-09-23 2012-09-21 Romidepsin and 5 - azacitidine for use in treating lymphoma

Publications (1)

Publication Number Publication Date
MX2014003467A true MX2014003467A (es) 2014-07-30

Family

ID=47045157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003467A MX2014003467A (es) 2011-09-23 2012-09-21 Romidepsina y 5-azacitidina para el tratamiento de linfoma.

Country Status (12)

Country Link
US (1) US20130085115A1 (enExample)
EP (1) EP2758067A1 (enExample)
JP (1) JP2014526558A (enExample)
KR (1) KR20140069225A (enExample)
CN (1) CN104114182A (enExample)
AU (1) AU2012312308B2 (enExample)
CA (1) CA2849708A1 (enExample)
HK (1) HK1200330A1 (enExample)
IL (1) IL231636A0 (enExample)
MX (1) MX2014003467A (enExample)
WO (1) WO2013043967A1 (enExample)
ZA (1) ZA201402151B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195634A1 (en) * 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
WO2018009855A1 (en) * 2016-07-07 2018-01-11 MiRagen Therapeutics, Inc. Methods for treating cutaneous t-cell lymphoma (ctcl) with mir-155 inhibitors
WO2021186855A1 (ja) * 2020-03-16 2021-09-23 株式会社マンダム T細胞性リンパ腫の指標の検出方法、及びその利用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH064872A (ja) 1992-06-19 1994-01-14 Sony Corp 光ディスク再生装置
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
AU2001280109A1 (en) 2000-09-01 2002-03-22 Fujisawa Pharmaceutical Co. Ltd. A method of producing fr901228
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
EP1482418A1 (en) 2003-05-28 2004-12-01 Sap Ag A data processing method and system
ES2444890T3 (es) * 2006-03-31 2014-02-27 Erasmus University Medical Center Rotterdam Nueva composición para el control del crecimiento tumoral
US20100137239A1 (en) * 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
CA2654566A1 (en) * 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
US20110269699A1 (en) * 2008-10-24 2011-11-03 Mitchell Keegan Cancer therapy

Also Published As

Publication number Publication date
ZA201402151B (en) 2015-06-24
HK1200330A1 (en) 2015-08-07
CN104114182A (zh) 2014-10-22
EP2758067A1 (en) 2014-07-30
CA2849708A1 (en) 2013-03-28
WO2013043967A1 (en) 2013-03-28
US20130085115A1 (en) 2013-04-04
IL231636A0 (en) 2014-05-28
AU2012312308A1 (en) 2013-05-02
AU2012312308B2 (en) 2015-11-19
KR20140069225A (ko) 2014-06-09
JP2014526558A (ja) 2014-10-06
NZ622752A (en) 2016-06-24

Similar Documents

Publication Publication Date Title
RU2543348C2 (ru) Способ лечения путем применения комбинированной терапии
JP6063628B2 (ja) 5−アザシチジンを用いる、非小細胞肺癌の治療方法
WO2020257665A1 (en) Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
CN108136207A (zh) 用于治疗癌症的联合疗法
US20150366936A1 (en) Inhibition of drug resistant cancer cells
JP5948332B2 (ja) Mll再構成白血病の治療法
AU2012312308B2 (en) Romidepsin and 5-azacitidine for use in treating lymphoma
AU2012316266B2 (en) Combination therapy for chemoresistant cancers
JP2024514024A (ja) 4’-チオ-5-アザ-2’-デオキシシチジンおよびベネトクラクスの併用療法
WO2013085902A1 (en) Combination therapy methods for treating an inflammatory breast cancer
CA3068096C (en) Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
JP7228169B2 (ja) 医薬組成物
NZ622752B2 (en) Romidepsin and 5 - azacitidine for use in treating lymphoma
US20130116298A1 (en) Antitumor agent or postoperative adjuvant chemotherapeutic agent for hepatocellular carcinoma treatment
AU2009230499B2 (en) Anti-tumor agent comprising cytidine derivative and carboplatin
KR20240139581A (ko) 골수에 작용하는 5-아자-4'-티오-2'-데옥시사이티딘의 최고 혈중농도를 정교하게 제어가능한 경구용 제형
CN118302169A (zh) 治疗癌症或血液疾病的方法
HK40025641B (zh) Mcl-1抑制剂与用於血液癌症的标准治疗的组合,其用途和药物组合物
HK1170667A (en) Antitumor agent or postoperative adjuvant chemotherapeutic agent for treatment of hepatocellular carcinoma
HK1150151A (en) Anti-tumor agent comprising cytidine derivative and carboplatin

Legal Events

Date Code Title Description
FA Abandonment or withdrawal